The recent sell off in the stock market has also put a damper on the market for initial public offerings (IPO), which was finally starting to show a nascent recovery after a dismal showing in 2009. (Learn more about the IPO market, see: The Murky Waters Of The IPO Market.)
Over the last two years, the IPO market slowed dramatically, due to the fall in the stock market and risk aversion by investors. In 2007, 272 IPO deals came to market, raising $60 billion. Only 43 IPOs were priced in 2008, raising $28 billion, followed by 63 in 2009, raising an even lower $21.9 billion.

The low point was the first quarter of 2009, when only one deal was priced. Mead Johnson (NYSE:MJN), which was spun out by Bristol-Myers Squibb (NYSE:BMY), sold shares at $24 per share. That turned out to be one of the best deals in recent memory, as the stock is selling near $46, close to a 100% return in a year.

Things started to pick up toward the end of 2009. The fourth quarter saw 32 IPOs come to market, followed by seven in January, 2010.

IN PICTURES: 7 Forehead-Slapping Stock Blunders

Current Problems
The market sell off has changed the tone of the market. Terreno Realty has cut its offering size twice in the last two weeks. The company was originally scheduled to sell 15 million shares at $20 per share, but cut that to 10 million shares in January, 2010. The company is now reportedly offering 8.75 million shares, raising approximately $175 million.

Terreno Realty is a real estate investment trust (REIT) that intends to use the funds to acquire industrial properties in six coastal areas in the United States.

Many companies that filed for IPOs didn't even make it as far as Terreno Realty, as several postponed deals. Patriot Risk Management, which provides worker's compensation insurance, postponed its deal for a week, after cutting the pricing range from $12-8 per share.

Imperial Capital, an investment bank headquartered in California, shelved its IPO due to market conditions.

Current Successes
One of the few success stories so far in 2010 is Ironwood Pharmaceuticals (Nasdaq:IRWD), a biotechnology company that is developing a drug to treat irritable bowel syndrome. The company priced its deal in early February, selling 16.67 million shares at $11.25 per share, below the expected range of $14-16.

In November 2009, Ironwood Pharmaceuticals announced successful Phase III clinical trial results for Linaclotide. The company is developing the drug in partnership with Forest Labs (NYSE:FRX)

The Bottom Line
The IPO market, which started to rebound late last year as confidence returned to equity markets, may be in for a tougher road than many thought, as the IPO market gets caught up in the recent market sell off.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Investing

    Asset Manager Ethics: Acting With Competence and Diligence

    Managers must make investment decisions based on their personal investment process, which in turn should be based on solid research and due diligence.
  2. Forex Education

    Understanding The Income Statement

    Learn how to use revenue and expenses, among other factors, to break down and analyze a company.
  3. Stock Analysis

    Will J.C. Penney Come Back in 2016? (JCP)

    J.C. Penney is without a doubt turning itself around, but that doesn't guarantee the stock will respond immediately.
  4. Investing

    Time to Bring Active Back into a Portfolio?

    While stocks have rallied since the economic recovery in 2009, many active portfolio managers have struggled to deliver investor returns in excess.
  5. Economics

    Investing Opportunities as Central Banks Diverge

    After the Paris attacks investors are focusing on central bank policy and its potential for divergence: tightened by the Fed while the ECB pursues easing.
  6. Stock Analysis

    The Biggest Risks of Investing in Pfizer Stock

    Learn the biggest potential risks that may affect the price of Pfizer's stock, complete with a fundamental analysis and review of other external factors.
  7. Stock Analysis

    Allstate: How Being Boring Earns it Billions (ALL)

    A summary of what Allstate Insurance sells and whom it sells it to including recent mergers and acquisitions that have helped boost its bottom line.
  8. Options & Futures

    Cyclical Versus Non-Cyclical Stocks

    Investing during an economic downturn simply means changing your focus. Discover the benefits of defensive stocks.
  9. Markets

    PEG Ratio Nails Down Value Stocks

    Learn how this simple calculation can help you determine a stock's earnings potential.
  10. Investing

    How to Spot Secular Bull Markets vs. Secular Bear Markets

    A guide to identifying secular bull and bear markets.
  1. What does low working capital say about a company's financial prospects?

    When a company has low working capital, it can mean one of two things. In most cases, low working capital means the business ... Read Full Answer >>
  2. Do nonprofit organizations have working capital?

    Nonprofit organizations continuously face debate over how much money they bring in that is kept in reserve. These financial ... Read Full Answer >>
  3. Can a company's working capital turnover ratio be negative?

    A company's working capital turnover ratio can be negative when a company's current liabilities exceed its current assets. ... Read Full Answer >>
  4. Does working capital measure liquidity?

    Working capital is a commonly used metric, not only for a company’s liquidity but also for its operational efficiency and ... Read Full Answer >>
  5. How do I read and analyze an income statement?

    The income statement, also known as the profit and loss (P&L) statement, is the financial statement that depicts the ... Read Full Answer >>
  6. Can working capital be too high?

    A company's working capital ratio can be too high in the sense that an excessively high ratio is generally considered an ... Read Full Answer >>

You May Also Like

Trading Center